Supreme Court Rules Against Drugmaker in Patent Infringement Case

The U.S. Supreme Court has unanimously decided that a pharmaceutical company cannot solely rely on statements from a generic drug manufacturer to claim "induced infringement" of brand-name drug patents. The ruling clarifies that such claims under federal law cannot be based solely on product labeling, patient information leaflets, or press releases.